dc.contributor.author | Bayraktar, Zeki | |
dc.contributor.author | Albayrak, Selami | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:57:02Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:57:02Z | |
dc.date.issued | 2018 | en_US |
dc.identifier.citation | Bayraktar, Z. ve Albayrak, S. (2018). Antiplatelet (aspirin) therapy as a new option in the treatment of vasculogenic erectile dysfunction: A prospective randomized double-blind placebo-controlled study. International Urology and Nephrology, 50(3), 411-418. https://dx.doi.org/10.1007/s11255-018-1786-0 | en_US |
dc.identifier.issn | 0301-1623 | |
dc.identifier.issn | 1573-2584 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s11255-018-1786-0 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/2880 | |
dc.description | WOS: 000427128300004 | en_US |
dc.description | PubMed ID: 29344879 | en_US |
dc.description.abstract | To investigate the efficiency of antiplatelet (aspirin) therapy in vasculogenic erectile dysfunction (VED) patients with a high mean platelet volume. A total of 184 patients diagnosed with VED between the ages of 18 and 76 were randomly divided into two groups and treated for 6 weeks [group 1: 120 patients (mean age 48.3), aspirin 100 mg/day; group 2: 64 patients (mean age 47.7), placebo 100 mg/day]. The changes from baseline to end point in erectile function scores on the International Index of Erectile Function (IIEF-EF) and the number of patients who answered "yes" to questions 2 and 3 of the sexual encounter profile (SEP) were compared statistically. The mean baseline IIEF-EF scores in groups 1 and 2 were 14.1 +/- 4.9 and 14.3 +/- 5.2, respectively (p = 0.7966), the number of patients who answered "yes" to SEP-2 was 62 (51.6%) in group 1 and 32 (50%) in group 2 (p = 0.8366), and the number of patients who answered "yes" to SEP-3 was 38 (31.6%) in group 1 and 20 (31.2%) in group 2 (p = 0.9557). In the aspirin group, the changes from baseline to end point in the IIEF-EF, SEP-2, and SEP-3 scores were 7.2, 36.6, and 46.6%, respectively. In the placebo group, these changes were 2.0, 9.4, and 12.5%, respectively. When compared with the placebo group, aspirin-treated subjects showed a significant improvement in all three efficacy measures (p <0.0001). 100 mg of aspirin administered once a day significantly improved EF in men with VED. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Aspirin | en_US |
dc.subject | Antiplatelet | en_US |
dc.subject | Antithrombocytic | en_US |
dc.subject | Erectile Dysfunction | en_US |
dc.subject | Treatment | en_US |
dc.title | Antiplatelet (aspirin) therapy as a new option in the treatment of vasculogenic erectile dysfunction: A prospective randomized double-blind placebo-controlled study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | International Urology and Nephrology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-2493-2457 | en_US |
dc.authorid | 0000-0002-4245-7506 | en_US |
dc.identifier.volume | 50 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 411 | en_US |
dc.identifier.endpage | 418 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1007/s11255-018-1786-0 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q2 | en_US |